Author:
Bruce Nhu T.,Neil William P.,Zivin Justin A.
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine
Reference23 articles.
1. Bambauer KZ, Johnston SC, Bambauer DE, Zivin JA. Reasons why few patients with acute stroke receive tissue plasminogen activator. Arch Neurol. 2006;63:661–4.
2. Saver JL. Hemorrhage after thrombolytic therapy for stroke: The clinically relevant number needed to harm. Stroke. 2007;38:2279–83. A re-analysis of the NINDS trial showed the clinically relevant number needed to harm for a patient to have a worse outcome attributable to tPA was 126.
3. Hanss M, Collen D. Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: Modulation by thrombin, endotoxin, and histamine. J Lab Clin Med. 1987;109:97–104.
4. Hoylaerts M, Rijken DC, Lijnen HR, et al. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem. 1982;257:2912–9.
5. Sussman BJ, Fitch TSP. Thrombolysis with fibrinolysin in cerebral arterial occlusion. J Am Med Assoc. 1958;167:1705.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献